Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Approves GSK’s Anoro Ellipta, The First LABA/LAMA Combination

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA approved GSK’s Anoro Ellipta as the first LABA/LAMA combination product in the U.S. for the maintenance treatment of COPD Dec. 18, positioning GSK to launch a second respiratory product months after launching Breo Ellipta.

You may also be interested in...



FLAME Shoots LABA/LAMA Combos Up To First Choice In COPD

At the American Thoracic Society annual meeting, science committee chair says change in COPD treatment guidelines to favor LABA/LAMA as preferred option will be considered soon.

Boehringer Enters Asthma Market With New Indication For Spiriva Respimat

Spiriva – the first long-acting muscarinic antagonist approved for asthma – wins broad indication; sales target is likely sizeable patient population with uncontrolled disease.

Novartis Respiratory Franchise Sits On FDA Launch Pad; Can It Achieve Orbit?

EXPEDITION clinical program seems to satisfy U.S. requirements for firm’s COPD bronchodilators; now all Novartis needs is approval, some clinical differentiation – and perhaps a marketing partner.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

ID034708

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel